Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 22.42 | 19.71 | 15.02 | 16.87 | 20.27 | 45.31 | 24.26 | — | — | — | 20.82 | 353.46 | 29.03 | 40.78 | 158.88 | — | — | — | — | — | — |
| — | -56.5% | -38.1% | — | — | — | +16.5% | — | — | — | -86.9% | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.92 | 1.70 | 1.74 | 1.70 | 2.12 | 1.57 | 1.70 | 1.41 | 1.95 | 2.23 | 2.44 | 2.01 | 2.11 | 2.06 | 1.54 | 1.74 | 1.56 | 1.63 | 1.76 | 2.68 | 1.91 |
| — | +8.8% | +2.5% | +20.3% | +8.7% | -29.7% | -30.3% | -29.9% | -7.3% | +8.1% | +58.9% | +15.5% | +34.7% | +26.2% | -12.6% | -35.0% | -18.1% | -25.0% | -11.7% | +76.3% | +19.4% | |
| P/B Ratio | 2.92 | 3.04 | 2.95 | 3.10 | 3.82 | 2.87 | 3.03 | 2.51 | 2.69 | 2.56 | 2.82 | 2.32 | 2.44 | 2.21 | 1.93 | 1.94 | 1.56 | 1.43 | 1.31 | 1.82 | 2.08 |
| — | +5.8% | -2.6% | +23.5% | +42.1% | +12.1% | +7.5% | +8.3% | +10.0% | +15.7% | +45.6% | +19.4% | +56.9% | +54.4% | +47.6% | +6.5% | -25.0% | -35.1% | -38.5% | +2.4% | +19.6% | |
| P/FCF | 11.21 | 6.67 | 8.80 | 64.38 | 12.75 | 4.81 | 22.15 | 20.08 | 37.77 | 23.72 | 24.52 | 6.63 | 10.05 | 17.41 | 8.61 | — | — | — | — | — | — |
| — | +38.7% | -60.3% | +220.6% | -66.3% | -79.7% | -9.7% | +202.9% | +275.8% | +36.3% | +184.9% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 10.03 | 7.42 | 7.02 | 6.06 | 10.95 | 11.63 | 9.24 | 21.32 | — | 16.05 | 10.00 | 12.82 | 9.07 | 10.02 | 8.90 | 12.87 | 18.21 | 140.04 | — | — | 18.76 |
| — | -36.2% | -24.1% | -71.6% | — | -27.6% | -7.5% | +66.3% | — | +60.2% | +12.4% | -0.3% | -50.2% | -92.8% | — | — | -2.9% | — | — | — | +108.9% | |
| EV / EBIT | 21.32 | 10.95 | 11.48 | 7.89 | 12.93 | 27.08 | 17.82 | — | — | 134.60 | 11.69 | 41.99 | 16.80 | 21.98 | 22.19 | 125.85 | — | — | — | — | — |
| — | -59.6% | -35.6% | — | — | -79.9% | +52.4% | — | — | +512.5% | -47.3% | -66.6% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.0% | 62.4% | 51.8% | 96.2% | 49.1% | 64.7% | 62.9% | 57.9% | 57.5% | 58.2% | 64.2% | 59.4% | 63.5% | 63.7% | 64.7% | 61.5% | 60.8% | 52.2% | 46.8% | 44.4% | 53.1% |
| — | -3.6% | -17.7% | +66.1% | -14.6% | +11.2% | -2.0% | -2.6% | -9.5% | -8.7% | -0.7% | -3.3% | +4.5% | +22.0% | +38.1% | +38.5% | +14.4% | -3.5% | -26.0% | -22.4% | -14.4% | |
| Operating Margin | 9.2% | 15.2% | 16.3% | 19.5% | 10.0% | 6.6% | 13.3% | -2.3% | -13.8% | 3.7% | 14.8% | 5.1% | 13.6% | 10.6% | 9.3% | 1.9% | -6.0% | -17.5% | -29.8% | -38.9% | -6.8% |
| — | +131.4% | +22.7% | +948.8% | +172.5% | +75.5% | -10.1% | -145.0% | -201.6% | -64.8% | +59.5% | +164.5% | +328.5% | +160.9% | +131.1% | +105.0% | +12.9% | +45.3% | -633.0% | -6835.1% | -229.4% | |
| Net Margin | 8.9% | 9.3% | 12.4% | 11.1% | 10.6% | 4.0% | 8.0% | -5.4% | -16.3% | -1.7% | 13.2% | 0.9% | 7.5% | 5.4% | 1.3% | -4.5% | -10.3% | -20.2% | -31.2% | -39.6% | -8.5% |
| — | +129.7% | +56.1% | +306.4% | +165.0% | +344.1% | -40.0% | -714.6% | -316.1% | -130.9% | +883.1% | +119.5% | +173.5% | +126.5% | +104.3% | +88.6% | -20.1% | +30.3% | -19897.3% | -523.9% | -1142.7% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.2% | 4.3% | 5.3% | 5.3% | 5.0% | 1.9% | 3.6% | -2.4% | -5.3% | -0.5% | 3.9% | 0.3% | 2.2% | 1.6% | 0.4% | -1.3% | -2.6% | -4.4% | -5.7% | -8.8% | -2.3% |
| — | +125.6% | +48.7% | +319.7% | +194.1% | +495.5% | -7.7% | -1044.5% | -337.2% | -129.6% | +818.0% | +120.1% | +187.6% | +136.9% | +107.4% | +85.7% | -10.0% | +38.7% | -13352.9% | -371.7% | -1133.1% | |
| ROA | 5.8% | 1.7% | 2.1% | 1.9% | 1.8% | 0.6% | 1.2% | -0.8% | -2.2% | -0.2% | 2.0% | 0.1% | 1.1% | 0.8% | 0.2% | -0.6% | -1.2% | -2.0% | -2.7% | -3.9% | -0.9% |
| — | +161.2% | +69.3% | +341.4% | +180.2% | +360.4% | -39.2% | -721.1% | -292.6% | -132.4% | +960.9% | +122.7% | +198.5% | +138.5% | +107.1% | +85.4% | -23.3% | +33.3% | -14373.7% | -393.8% | -1100.6% | |
| ROIC | 8.2% | 5.3% | 5.0% | 6.3% | 2.4% | 1.2% | 2.2% | -0.4% | -2.1% | 0.7% | 2.9% | 0.9% | 2.4% | 1.7% | 1.3% | 0.2% | -0.7% | -1.7% | -2.6% | -3.9% | -0.7% |
| — | +352.7% | +132.5% | +1846.5% | +211.7% | +59.8% | -25.4% | -138.3% | -188.0% | -56.1% | +120.6% | +295.3% | +466.3% | +196.0% | +150.1% | +106.2% | +6.7% | +45.4% | -520.7% | -5831.1% | -221.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.60 | 0.55 | 0.58 | 0.60 | 0.64 | 1.35 | 1.40 | 1.46 | 1.45 | 0.59 | 0.60 | 0.62 | 0.63 | 0.66 | 0.84 | 0.85 | 0.85 | 0.85 | 0.83 | 0.80 | 1.06 |
| — | -58.9% | -58.5% | -58.7% | -56.1% | +126.9% | +134.6% | +133.3% | +130.9% | -9.9% | -29.0% | -26.2% | -26.2% | -22.7% | +1.6% | +5.7% | -19.3% | -20.2% | -7.9% | -15.6% | +9.5% | |
| Debt / EBITDA | 1.88 | 5.50 | 5.50 | 4.59 | 7.10 | 16.72 | 12.69 | 34.25 | — | 14.36 | 8.16 | 13.03 | 8.62 | 10.56 | 11.64 | 16.47 | 27.69 | 227.55 | — | — | 25.95 |
| — | -67.1% | -56.7% | -86.6% | — | +16.5% | +55.6% | +162.8% | — | +36.0% | -29.9% | -20.9% | -68.9% | -95.4% | — | — | +6.7% | — | — | — | +95.5% | |
| Current Ratio | 2.71 | 2.91 | 3.12 | 2.71 | 2.58 | 2.54 | 2.66 | 2.72 | 2.74 | 3.97 | 3.95 | 3.57 | 3.70 | 3.74 | 2.90 | 3.46 | 3.79 | 3.35 | 3.79 | 3.68 | 2.25 |
| — | +14.4% | +17.4% | -0.6% | -5.9% | -35.9% | -32.7% | -23.8% | -25.8% | +6.1% | +36.2% | +3.2% | -2.4% | +11.7% | -23.5% | -5.8% | +68.1% | +56.1% | +71.6% | +69.6% | +3.2% | |
| Quick Ratio | 2.19 | 2.41 | 2.52 | 2.19 | 2.04 | 1.96 | 1.98 | 2.02 | 1.97 | 3.07 | 3.12 | 2.81 | 2.91 | 2.89 | 2.08 | 2.40 | 2.62 | 2.39 | 2.74 | 2.74 | 1.53 |
| — | +22.7% | +27.5% | +8.7% | +3.8% | -36.2% | -36.6% | -28.1% | -32.4% | +6.3% | +50.2% | +16.9% | +11.2% | +21.1% | -24.4% | -12.4% | +71.1% | +71.9% | +84.8% | +96.7% | +8.8% | |
| Interest Coverage | 5.78 | 11.20 | 9.67 | 2.38 | 8.15 | 1.94 | 3.14 | -1.29 | -12.51 | 0.51 | 6.51 | 1.16 | 2.80 | 1.74 | 1.28 | 0.24 | -0.68 | -1.82 | -2.92 | -5.95 | -1.86 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ANIP stock.
ANI Pharmaceuticals, Inc.'s current P/E is 22.4x. The average P/E over the last 4 quarters is 18.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
ANI Pharmaceuticals, Inc.'s current operating margin is 9.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ANI Pharmaceuticals, Inc.'s business trajectory between earnings reports.